Short-term treatment of painful osteoarthritis of the knee with oral enzymes. A randomised, double-blind study versus diclofenac

Clinical Drug Investigation

Volumn 19, Issue 1, 2000, Pages 15-23

  Klein, G ^a,b   Kullich, W ^b  

^a Rehab Ctr for Rheum/C D   (Austria)

^b Ludwig Boltzmann I for R of I D   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BROMELAIN; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PHLOGENZYM; RUTOSIDE; TRYPSIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DUODENUM ULCER; ENTERIC COATED TABLET; ENZYME THERAPY; FEMALE; HEADACHE; HUMAN; KNEE ARTHRITIS; KNEE FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS BRADYCARDIA; STATISTICAL ANALYSIS;

EID: 0033956366     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019010-00003     Document Type: Article

References (53)

1. Altman RD. Kriterien für die Klassifizierung der klinischen Arthrose. EULAR Bull 1992; 3: 81-3
2. Hochherg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Arthritis Rheum 1995; 38: 1541-6
3. Fries JF, Williams CA, Bloch DA. The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1991; 34: 1353-60
4. Tamblyn R, Berkson L, Dauphinee WD, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Mod 1997; 127: 429-38
5. Ament PW, Childers RS. Prophylaxis and treatment of NSAID-induced gastropathy. Am Fam Physician 1997; 4: 1323-6
6. Bagge E, Traub M, Crotty M, et al. Are rheumatoid arthritis patients more willing to accept non-steroidal anti-inflammatory drug treatment risks than osteoarthritis patients? Br J Rheumatol 1997; 36: 470-2
7. Mohammed S, Croom DW. Gastropathy due to celecoxib, a cyclo-oxygenase-2-inhihitor. N Engl J Med 1999; 340: 2005-6
8. Hawkey C, Kahan A, Steinbrück K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-Scale International Study Safety Assessment. Br J Rheumatol 1998; 37: 937-45
9. Klein G, Kullich W, Brugger A. Phlogenzym in der Behandlung der Periarthropathia humeroscapularis tendopathica simplex. Arzt Praxis 1997; 51: 879-85
10. Miehlke K. Rheumabehandlung mit Enzymen ist mehr als nur antiphlogistische Therapie. In: Medizinische Enzym-Forschungsgesellschaft e.V. Systemische Enzym-therapie, 15th working symposium, Munich, Germany. Gräfelfing: Forum Medizin Verlag, 1991
11. Singer F, Oberleitner H. Ein Beitrag zur medikamentösen Therapie der aktivierten Arthrose. Zur Effektivität eines Enzymgemisches versus Diclofenac. Wien Med Wochenschr 1996; 3: 55-8
12. Vogler W. Der Stellenwert der Enzymtherapie bei entzündlich-rheumatischen Erkrankungen. Medizinische Woche Baden-Baden 1990. Natur- und Ganzheitsmedizin 1991; 1 (Suppl.): 23-7
13. Emancipator SN, Chintalacharuvu SR, Urankar Nagy N, et al. Effects of oral enzymes in collagen II induced arthritis in mice. Int J Immunother 1997; 13: 67-74
14. Desser L, Rehberger A, Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro. Cancer Biother 1994; 9: 253-63
15. Lehmann VP. Immunomodulation by proteolytic enzymes. Nephrol Dial Transplant 1996; 11: 953-5
16. Subba Rao C, Nagy NU, Emancipator SN. Phlogenzym® protease therapy ameliorates injury in experimental autoimmune arthritis induced by collagen II. B Lymphocytes and Autoimmunity. International Conference; 1996 May 22; Prague, Czech Republic: The New York Academy of Science
17. Steffen C, Menzel J. Grundlagenuntersuchungen zur Enzymtherapie bei Immunkomplexkrankheiten. Wien Klin Wochenschr 1985; 97: 376-85
18. Ernst E. Orale Therapie mit proteolytischen Enzymen: Effekte auf hämorheologische Parameter. Perfusion 1994; 12: 440-1
19. Guggenbichler JP. Einfluß hydrolytischer Enzyme auf Thrombusbildung und Thrombolyse. Med Welt 1988; 39: 277-80
20. Hale LP, Haynes BF. Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8 and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. Am Assoc Immunol 1992; 149: 3809-16
21. Kleef R, Delohery TM, Bovbjerg DH. Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease 5. Pathobiology 1996; 64: 339-46
22. Munzig E, Eckert K, Harrach T, et al. Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. FEBS Lett 1994; 351: 215-8
23. Mojcik C, Shevach EM. Adhesion molecules. Arthritis Rheum 1997; 40: 991-1004
24. Kleine MW. Einführung in die systemische Enzymtherapie. In: Wrba H, Kleine MW, Miehlke K, et al., editors. Systemische Enzymtherapie. Munich: MMV Medizin Verlag, 1996: 18-27
25. Seifert J, Siebrecht D, Lange JP, et al. The quantitative absorption of orally administered proteins and histological evidence of enzymes in the wound. In: Gardner MLG, Steffens KJ, editors. Absorption of orally administered enzymes. Berlin: Springer Verlag, 1995: 29-38
26. Lequesne M. Clinical features, diagnostic criteria, functional assessments and radiological classification of osteoarthritis (excluding the spine). Rheumatology 1982; 7: 1-10
27. Lequesne MG, Mery C, Samson M, et al. Indexes of severity for osteoarthritis of the hip and the knee. Scand J Rheumatol 1987; 65: 85-9
28. Lequesne M, Klinische und röntgenologische Verlaufsbeobachtung bei Hüft- und Kniearthrosen. Methoden und Ergebnisse. Z Rheumatol 1994; 53: 243-9
29. Scott PJ, Huskisson EC. Graphic representation of pain. Pain 1976; 2: 175-84
30. Fassbender HG, Zwick J. Neue Forschungsergebnisse auf dem Gebiet der Osteoarthrose. Wien Med Wochenschr 1995; 145: 96-8
31. Baskin WN, Ivey KJ. Aspirin-induced ultrastructural changes in human gastric mucosa: correlation with potential difference. Ann Intern Med 1976; 85: 299-303
32. Miller DR. Treatment of nonsteroidal anti-inflammatory drug induced gastropathy. Clin Pharm 1992; 11: 690-704
33. Shallcross TM, Heatley RV. Effect of nonsteroidal anti-inflammatory drugs on dyspeptic symptoms. BMJ 1990; 300: 368-9
34. Soll AH, Weinstein WM, Kurata J, et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114: 307-19
35. Clinch D, Banerjee AK, Ostick G. Absence of abdominal pain in elderly patients with peptic ulcer. Age Ageing 1984; 13: 120-3
36. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156: 1530-6
37. Jobanputra P, Nuki G. Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. Rheumatology 1994; 6: 433-9
38. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988; 84 Suppl. 2A: 20-4
39. Greene JM, Winickoff RN. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. Arch Intern Med 1992; 152: 1995-2002
40. Miehlke K. Enzyme minimieren Risiken der Rheumatherapie. In: Medizinische Enzym-Forschungsgesellschaft e.V. Systemische Enzymtherapie, 10th working symposium Frankfurt, Germany. Gräfelfing: Forum Medizin Verlag, 1990
41. Reinbold H, Maehder K. Die biologische Alternative in der Therapie entzündlicher rheumatischer Erkrankungen. Z Allgemeinmed 1981; 57: 2397-402
42. Wörschhauser S. Konservative Therapie der Sportverletzungen. Enzympräparate für Therapie und Prophylaxe. Allgemeinmedizin 1990; 19: 173-7
43. Kullich W, Pöllmann G, Zmerekar Ch, et al. Stellenwert der Bestimmung von Pepsinogen I im Serum als Screening-methode zur Früherkennung gastroduodenaler Läsionen und als Verlaufskontrolle unter der Therapie mit nichtsteroidalen Antirheumatika. Z Rheumatol 1991; 50: 39-45
44. Kullich W, Wallner H, Klein G. Die Bestimmung von Serumpepsinogen I und II zur Beurteilung der gastroduodenalen Verträglichkeit von S(+)-Ibuprofen. Wien Klin Wochenschr 1994; 106/7: 208-11
45. Veale DJ, Maple C. Cell adhesion molecules in rheumatoid arthritis. Drugs Aging 1996; 9: 87-92
46. Maheu E, Mazières B, Valat J-P, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis Rheum 1998; 41: 81-91
47. Steffen C, Menzel J. Enzymabbau von Immunkomplexen. Z Rheumatol 1983; 42: 249-55
48. Innerfield I, Luongo F. Analgesic and anti-inflammatory effects of orally given streptokinase. Proc Soc Exp Biol Med 1963; 113: 465-8
49. Bodi T. The effects of oral bromelains on tissue permeability to antibiotics and pain response to bradykinin: double blind studies on human subjects. Clin Med 1966; 73: 61-5
50. Prado JL. Proteolytic enzymes as kininogenases. In: Erdös EG, Wilde AF, editors. Bradykinin, kallidin and kallikrein. Berlin: Springer, 1970
51. Murachi T, Miyake T. Action of stem bromelain on bovine bradykininogen II and bradykinin. Physiol Chem Phys 1970; 2: 97-104
52. Mineshita S, Nagai Y. Hydrolysis of bradykinin by stem bromelain. Jpn J Pharmacol 1977; 27: 170-2
53. Farmer SG, editor. The kinin system. London: Academic Press, 1997